In a statement, the company accused Hims of attempting to unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill, calling the move illegal mass compounding that poses a significant risk to patient safety. Novo pledged to take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. On a call with analysts that same day, Novo Nordisk CEO Mike Doustdar argued that consumers would be wasting $49 on the Hims product because, without Novos proprietary SNAC technology, the pill just simply doesnt work. Former FDA Commissioner Dr
Though it was within the normal range, MK-677 caused a slight increase in prolactin levels
Layering traditional fasting onto GLP-1 use may amplify metabolic stress, increase hypoglycemia risk, or cause electrolyte imbalances if not carefully monitored by a qualified provider
Your pigmentation will stop getting worse
(aapcc.org/annual-reports, 2019)
Another compounding trade group, the Alliance for Pharmacy Compounding, thanked the FDA for the grace period but insisted that the FDAs tirzepatide decision is not necessarily the end of the story. APC CEO Scott Brunner highlighted the ongoing litigation in a statement, writing that the agencys ruling was not a decision by a court. Its a unilateral action by the agency, so dont confuse the two, Brunner said, adding that he anticipated the court would also consider the perspective of compounders